Erlangen, Germany-based Siemens Healthineers AG announces that it has successfully completed the acquisition of Palo Alto, Calif.-based Varian Medical Systems, a deal previously announced in August 2020. Company officials say the combined company will create a highly integrated portfolio of imaging, laboratory diagnostics, artificial intelligence (AI), and treatment for the global fight against cancer with significant potential for increased value creation.

“With Varian, Siemens Healthineers has the most comprehensive portfolio in the med-tech sector, which offers the company considerable potential for value creation. With a highly integrated approach, Siemens Healthineers will take the global fight against cancer to a new level,” says Dr. Ralf P. Thomas, chairman of the supervisory board of Siemens Healthineers AG.

Chris Toth, CEO of Varian, a Siemens Healthineers company, also spoke out about the acquisition, commenting: “Through the transformative combination of Varian and Siemens Healthineers, our united company will address the growing need for personalized, data-driven diagnosis and precision cancer care that enables us to fight back against globally increasing cancer rates.”

Specifically, Varian and Siemens Healthineers are building on the long-standing strategic partnership called “EnVision” to establish a comprehensive digital, diagnostic, and therapeutic ecosystem that includes treatment management. With Varian, Siemens Healthineers will leverage AI-assisted analytics to advance the development and delivery of data-driven precision care and redefine cancer diagnosis, care delivery, and post-treatment survivorship.

Moreover, through early and accurate detection as well as more efficient diagnosis, increased treatment quality and access, Siemens Healthineers will support and accelerate Varian’s mission to reduce uncertainty for cancer patients and increase the level of cancer survivorship.